ANDA 207426, held by Sagent Pharms Inc. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 207426 (Sodium Nitroprusside), held by Sagent Pharms Inc, was first approved by FDA on Dec 8, 2016, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 8, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Nitroprusside25MG/ML ยท injectable;injection | Sodium Nitroprusside | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters